These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29885517)

  • 1. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data.
    Natale G; Bocci G
    Cancer Lett; 2018 Sep; 432():28-37. PubMed ID: 29885517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor endothelial cells as a potential target of metronomic chemotherapy.
    Kim JY; Kim YM
    Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
    Qin RS; Zhang ZH; Zhu NP; Chen F; Guo Q; Hu HW; Fu SZ; Liu SS; Chen Y; Fan J; Han YW
    BMC Cancer; 2018 Oct; 18(1):967. PubMed ID: 30305062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.
    Naumov GN; Akslen LA; Folkman J
    Cell Cycle; 2006 Aug; 5(16):1779-87. PubMed ID: 16931911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The host support niche as a control point for tumor dormancy: implications for tumor development and beyond.
    Hahnfeldt P
    Adv Exp Med Biol; 2013; 734():19-35. PubMed ID: 23143973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
    Indraccolo S
    Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
    Ferdous T; Harada K; Kin T; Harada T; Ueyama Y
    Int J Oncol; 2013 Jul; 43(1):271-9. PubMed ID: 23695365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of pro- and anti-angiogenic signals by endothelial cells.
    Kazerounian S; Lawler J
    J Cell Commun Signal; 2018 Mar; 12(1):171-179. PubMed ID: 29264709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy.
    Schättler H; Ledzewicz U; Amini B
    J Math Biol; 2016 Apr; 72(5):1255-80. PubMed ID: 26089097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of main pro- and anti-angiogenic factors in tumor angiogenesis.
    Huang Z; Bao SD
    World J Gastroenterol; 2004 Feb; 10(4):463-70. PubMed ID: 14966899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
    Cicchelero L; Denies S; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
    Cancer Lett; 2017 Aug; 400():205-218. PubMed ID: 27693635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
    Hida K; Kikuchi H; Maishi N; Hida Y
    Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
    Yuan F; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
    Oncol Rep; 2015 Apr; 33(4):1753-62. PubMed ID: 25634241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
    Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
    Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.